Created in 2002 (United States), MULTIPLE PATHWAYS, MULTIPLE TARGETS: DRUG DISCOVERY FOR CELGENE own 126 sister brands and 17477 competing brands. The MULTIPLE PATHWAYS, MULTIPLE TARGETS: DRUG DISCOVERY FOR CELGENE brand is owned by Celgene, a company listed in New York. MULTIPLE PATHWAYS, MULTIPLE TARGETS: DRUG DISCOVERY FOR CELGENE belongs to the Drug Manufacturers business sector.
Buy Celgene share with
(0% commission and fractional shares)
Your capital is subject to risk. Other fees apply. For more information, visit etoro.com/trading/fees.
Other brands
Celgene
-
A
-
B
-
C
- COMPROMISO 360
- CELGENE INSTITUTE FOR TRANSLATIONAL RESEARCH EUROPE (CITRE)
- CELGENE THALIDOMIDE
- C2ARE
- CELGENE i-access
- CELGENECARE
- CANCERCAN
- cintre
- CONTINUUM
- CELG
- CHIMERIC VIGOR
- CELMOD
- CELGENE MULTIPLE MYELOMA RESOURCE CENTER
- CELGENE AVILOMICS RESEARCH
- CELGENE MATRIX
- CYTUNE
- CITRE
- CELGENE INSTITUTE FOR TRANSLATIONAL RESEARCH EUROPE
- CANCER
- CELGENE COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
-
D
-
E
-
F
-
G
-
H
-
I
-
K
-
L
-
M
- MULTIPLE PATHWAYS, MULTIPLE TARGETS
- MYELOMA ALLY
- MM 013
- MAPP Multinational Assessment of Psoriasis and Psoriatic Arthritis Navigating the Course of Psoriatic Disease
- MATRIX Medical Affairs Tracking Reporting and Information Xchange
- MATRIX: MEDICAL AFFAIRS TRACKING REPORT AND INFORMATION XCHANGE
- MAINSAIL
- mpact
-
N
-
O
-
P
-
Q
-
R
-
S
-
T
-
V
